Advertisement

Pediatric Drugs

, Volume 21, Issue 2, pp 59–70 | Cite as

Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm

  • Doralina L. AnghelescuEmail author
  • Jessica Michala Tesney
Therapy in Practice

Abstract

Neuropathic pain in pediatric oncology can be caused by distinct lesions or disease processes affecting the somatosensory system, including chemotherapy-related neuronal injury, solid tumor-related involvement of neural structures, post-surgical neuropathic pain—including phantom limb pain and pain after limb-sparing surgery—and the complex circumstances of neuropathic pain at the end of life. Treatment algorithms reflect the general treatment principles applied for adult neuropathic pain, but the dose regimens applied in children are modest and rarely escalated to the maximum doses to optimize analgesic efficacy. Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach. Gabapentinoids and tricyclic antidepressants are recommended as first-line therapy. Methadone, ketamine, and lidocaine may be useful adjuvants in selected patients. Prospective studies extended over a substantial length of time are recommended because of the nature of neuropathic pain as persistent, chronic pain and based on the need for sufficient time to escalate medication dose regimens to full analgesic efficacy.

Notes

Compliance with Ethical Standards

Conflicts of interest

Doralina L. Anghelescu, Jessica Michala Tesney have no conflicts of interest that are directly relevant to the content of this article.

Funding

The preparation of this manuscript was supported in part by the National Cancer Institute Cancer Center Support Core Grant 5P25CA023944 and ALSAC. Funding for the work done by JMT was provided by grant R25CA23944 from the National Cancer Institute.

Supplementary material

40272_2018_324_MOESM1_ESM.pdf (62 kb)
Supplementary material 1 (PDF 62 kb)

References

  1. 1.
    Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.Google Scholar
  2. 2.
    Hansson PT, Attal N, Baron R, Cruccu G. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain. 2009;13(5):439–40.Google Scholar
  3. 3.
    Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25(5):553–9.Google Scholar
  4. 4.
    Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22(14):2909–17.Google Scholar
  5. 5.
    Chandler A, Williams JE. Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage. 2000;20(2):82–6.Google Scholar
  6. 6.
    Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. J Pain Symptom Manage. 2007;34(2):183–9.Google Scholar
  7. 7.
    Magnowska M, Izycka N, Kapola-Czyz J, Romala A, Lorek J, Spaczynski M, et al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy. Ginekol Pol. 2018;89(4):201–5.Google Scholar
  8. 8.
    Mishra S, Bhatnagar S, Goyal GN, Rana SPS, Upadhya SP. A Comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Med. 2011;29(3):177–82.Google Scholar
  9. 9.
    Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110–8.Google Scholar
  10. 10.
    Ross JR, Goller K, Hardy J, Riley J, Broadley K, A’Hern R, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med. 2005;8(6):1118–26.Google Scholar
  11. 11.
    Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105–11.Google Scholar
  12. 12.
    Jongen JL, Huijsman ML, Jessurun J, Ogenio K, Schipper D, Verkouteren DR, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage. 2013;46(4):581–90.Google Scholar
  13. 13.
    Mishra S, Bhatnagar S, Gupta D, Nirwani Goyal G, Jain R, Chauhan H. Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study. Am J Hosp Palliat Care. 2008–2009;25(6):447–51.Google Scholar
  14. 14.
    Smith EM, Bridges CM, Kanzawa G, Knoerl R, Kelly JPt, Berezovsky A, et al. Cancer treatment-related neuropathic pain syndromes–epidemiology and treatment: an update. Curr Pain Headache Rep. 2014;18(11):459.Google Scholar
  15. 15.
    Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.Google Scholar
  16. 16.
    Howard RF, Wiener S, Walker SM. Neuropathic pain in children. Arch Dis Child. 2014;99(1):84–9.Google Scholar
  17. 17.
    Jacob E. Neuropathic pain in children with cancer. J Pediatr Oncol Nurs. 2004;21(6):350–7.Google Scholar
  18. 18.
    Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932–7.Google Scholar
  19. 19.
    Lavoie Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36(5):E49–60.Google Scholar
  20. 20.
    Lavoie Smith EM, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015;20(1):37–46.Google Scholar
  21. 21.
    Madden K, Bruera E. Very-low-dose methadone to treat refractory neuropathic pain in children with cancer. J Palliat Med. 2017;20(11):1280–3.Google Scholar
  22. 22.
    Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Neuropathic pain in children: Special considerations. Mayo Clin Proc. 2010;85(3 Suppl):S33–41.Google Scholar
  23. 23.
    Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(7):1147–53.Google Scholar
  24. 24.
    Butkovic D, Toljan S, Mihovilovic-Novak B. Experience with gabapentin for neuropathic pain in adolescents: report of five cases. Paediatr Anaesth. 2006;16(3):325–9.Google Scholar
  25. 25.
    Keskinbora K, Pekel AF, Aydinli I. The use of gabapentin in a 12-year-old boy with cancer pain. Acta Anaesthesiol Scand. 2004;48(5):663–4.Google Scholar
  26. 26.
    Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol. 2012;54(4):347–52.Google Scholar
  27. 27.
    Anghelescu DL, Steen BD, Wu H, Wu J, Daw NC, Rao BN, et al. Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatr Blood Cancer. 2017.  https://doi.org/10.1002/pbc.26162.Google Scholar
  28. 28.
    Burgoyne LL, Billups CA, Jiron JL, Jr., Kaddoum RN, Wright BB, Bikhazi GB, et al. Phantom limb pain in young cancer-related amputees: recent experience at St Jude children’s research hospital. Clin J Pain. 2012 Mar-Apr;28(3):222-5.Google Scholar
  29. 29.
    Snaman JM, Baker JN, Ehrentraut JH, Anghelescu DL. Pediatric oncology: managing pain at the end of life. Paediatr Drugs. 2016;18(3):161–80.Google Scholar
  30. 30.
    Gupta R, Bhaskar A. Chemotherapy-induced peripheral neuropathic pain. BJA Education. 2016;16(4):115–9.Google Scholar
  31. 31.
    Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep. 2006;10(4):275–8.Google Scholar
  32. 32.
    Krumova EK, Geber C, Westermann A, Maier C. Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep. 2012;12(4):393–402.Google Scholar
  33. 33.
    Gilchrist LS, Tanner L. The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer. 2013;21(3):847–56.Google Scholar
  34. 34.
    Morgan KJ, Anghelescu DL. A review of adult and pediatric neuropathic pain assessment tools. Clin J Pain. 2017;33(9):844–52.Google Scholar
  35. 35.
    Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–51.Google Scholar
  36. 36.
    Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153–69.Google Scholar
  37. 37.
    Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13–21.Google Scholar
  38. 38.
    Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289–305.Google Scholar
  39. 39.
    Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.Google Scholar
  40. 40.
    Finnerup NB, Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook? Pain Manag. 2016;6(1):1–3.Google Scholar
  41. 41.
    Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 2017;6(Suppl 1):25–33.Google Scholar
  42. 42.
    Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13(4):332–6.Google Scholar
  43. 43.
    Rasmussen VF, Lundberg V, Jespersen TW, Hasle H. Extreme doses of intravenous methadone for severe pain in two children with cancer. Pediatr Blood Cancer. 2015;62(6):1087–90.Google Scholar
  44. 44.
    Kajiume T, Sera Y, Nakanuno R, Ogura T, Karakawa S, Kobayakawa M, et al. Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J Palliat Med. 2012;15(6):719–22.Google Scholar
  45. 45.
    Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol. 2001;23(9):616–9.Google Scholar
  46. 46.
    Anghelescu DL, Kelly CN, Steen BD, Wu J, Wu H, DeFeo BM, et al. Mirror therapy for phantom limb pain at a pediatric oncology institution. Rehabil Oncol. 2016;34(3):104–10.Google Scholar
  47. 47.
    Akkurt HE, Gumus H, Goksu H, Odabasi OF, Yilmaz H. Gabapentin treatment for neuropathic pain in a child with sciatic nerve injury. Case Rep Med. 2015;2015:873157.Google Scholar
  48. 48.
    Brown S, Johnston B, Amaria K, Watkins J, Campbell F, Pehora C, et al. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. Scand J Pain. 2016;13:156–63.Google Scholar
  49. 49.
    Orellana Silva M, Yanez V, Hidalgo G, Valenzuela F, Saavedra R. 5% lidocaine medicated plaster use in children with neuropathic pain from burn sequelae. Pain Med. 2013;14(3):422–9.Google Scholar
  50. 50.
    Taylor M, Jakacki R, May C, Howrie D, Maurer S. Ketamine PCA for treatment of end-of-life neuropathic pain in pediatrics. Am J Hosp Palliat Care. 2015;32(8):841–8.Google Scholar
  51. 51.
    Yazde Puleio ML, Gomez KV, Majdalani A, Pigliapoco V, Santos Chocler G. Opioid treatment for mixed pain in pediatric patients assisted by the Palliative Care team. Five years of experience. Arch Argent Pediatr. 2018;116(1):62–4.Google Scholar
  52. 52.
    DeMoss P, Ramsey LH, Karlson CW. Phantom limb pain in pediatric oncology. Front Neurol. 2018;9:219.Google Scholar
  53. 53.
    Anghelescu DL, Faughnan LG, Baker JN, Yang J, Kane JR. Use of epidural and peripheral nerve blocks at the end of life in children and young adults with cancer: the collaboration between a pain service and a palliative care service. Paediatr Anaesth. 2010;20(12):1070–7.Google Scholar
  54. 54.
    Nayak S, Cunliffe M. Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: report of five cases. Paediatr Anaesth. 2008;18(6):554–8.Google Scholar
  55. 55.
    Anghelescu DL, Faughnan LG, Hankins GM, Ward DA, Oakes LL. Methadone use in children and young adults at a cancer center: a retrospective study. J Opioid Manag. 2011;7(5):353–61.Google Scholar
  56. 56.
    Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16(3):191–8.Google Scholar
  57. 57.
    Zeltzer LK, Tsao JC, Stelling C, Powers M, Levy S, Waterhouse M. A phase I study on the feasibility and acceptability of an acupuncture/hypnosis intervention for chronic pediatric pain. J Pain Symptom Manage. 2002;24(4):437–46.Google Scholar
  58. 58.
    Butkovic D, Tot OK. Laser acupuncture treatment of neuropathic pain in a boy with brain tumour. Compl Ther Med. 2017;35:53–6.Google Scholar
  59. 59.
    Bernatzky G, Presch M, Anderson M, Panksepp J. Emotional foundations of music as a non-pharmacological pain management tool in modern medicine. Neurosci Biobehav Rev. 2011;35(9):1989–99.Google Scholar
  60. 60.
    Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manage. 2012;43(1):87–95.Google Scholar
  61. 61.
    Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ. A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. J Pain Palliat Care Pharmacother. 2013;27(4):359–64.Google Scholar
  62. 62.
    Park HS, Kim WJ, Kim HG, Yoo SH. Scrambler therapy for the treatment of neuropathic pain related to leukemia in a pediatric patient: a case report. Medicine (Baltimore). 2017;96(45):e8629.Google Scholar
  63. 63.
    Tomasello C, Pinto RM, Mennini C, Conicella E, Stoppa F, Raucci U. Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: a preliminary study. Pediatr Blood Cancer. 2018;6:e27064.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Anesthesia, Department of Pediatric MedicineSt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations